GlassScriptPhysician profile
Roberto E Ochoa Planchart
NPI 1962659466
$10,107.64
in general payments reported to CMS, 2019-2025
66 companies · $3,759 in 2025
The $3,759 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.48 · 2023: $2,552 · 2024: $3,764 · 2025: $3,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,785 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,785.18 |
| Education | $288.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $728.15 | 2023-2025 | |
| Daiichi Sankyo INC. | $567.40 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $538.46 | 2022-2025 | Farxiga, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $535.54 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $471.99 | 2023-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $434.51 | 2023-2025 | Ojjaara |
| Janssen Biotech, INC. | $400.99 | 2023-2025 | Rybrevant, Carvykti, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $379.67 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Lilly USA, LLC | $334.82 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $328.71 | 2023-2025 | Alunbrig, Ninlaro, Vpriv |
| Pharmaessentia USA Corporation | $289.79 | 2024-2025 | Besremi |
| Tempus Ai, INC | $279.40 | 2024-2025 | Xt Cdx |
| Sobi, INC | $259.43 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $231.19 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.21 | 2024-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.09 | 2023-2025 | |
| Seagen INC. | $205.81 | 2023-2025 | Tukysa, Padcev, Tivdak |
| Genzyme Corporation | $205.44 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $191.56 | 2023-2025 | Mychoice Cdx, Myrisk, Precisetumor |
| Pharmacosmos Therapeutics INC. | $186.83 | 2023-2025 | Monoferric |
| Incyte Corporation | $180.56 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Jazz Pharmaceuticals INC. | $177.14 | 2023-2025 | Zepzelca |
| Genentech USA, INC. | $166.70 | 2023-2025 | Polivy, Tecentriq, Phesgo |
| Coherus Oncology, INC. | $142.42 | 2023-2025 | Udenyca, Loqtorzi |
| Adc Therapeutics America, INC. | $141.99 | 2023-2025 | |
| Mirati Therapeutics, INC. | $133.51 | 2023-2024 | Krazati |
| Eisai INC. | $121.69 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $115.11 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $106.01 | 2024-2025 | Onivyde |
| Emd Serono, INC. | $102.68 | 2023-2024 | Bavencio, Tepmetko |
| Regeneron Healthcare Solutions, INC. | $93.69 | 2024-2025 | Libtayo |
| Astellas Pharma US INC | $93.37 | 2023-2024 | Xospata, Padcev, Xtandi |
| Alexion Pharmaceuticals, INC. | $89.15 | 2023-2025 | Ultomiris |
| Kite Pharma, INC. | $79.53 | 2023 | Yescarta |
| Octapharma USA, INC. | $79.00 | 2023 | Octagam Immune Globulin (Human), Panzyga |
| Beigene USA, INC. | $65.01 | 2024-2025 | Tevimbra, Brukinsa |
| Array Biopharma INC | $61.14 | 2024 | Mektovi, Braftovi, Lorbrena |
| Adaptive Biotechnologies Corporation | $61.09 | 2024 | Clonoseq |
| Beone Medicines USA, INC. | $57.29 | 2025 | Tevimbra, Brukinsa |
| Rigel Pharmaceuticals, INC. | $56.68 | 2024 | Tavalisse, Rezlidhia |
| Gilead Sciences, INC. | $55.57 | 2024-2025 | Trodelvy |
| Deciphera Pharmaceuticals INC. | $54.43 | 2024 | Qinlock, Tgct |
| Sun Pharmaceutical Industries INC. | $53.69 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $52.39 | 2024-2025 | Provenge |
| Exelixis INC. | $49.30 | 2024 | Cabometyx |
| Stemline Therapeutics INC. | $48.59 | 2024-2025 | Orserdu |
| Novocure INC. | $48.50 | 2024-2025 | Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $48.10 | 2023-2024 | Monjuvi |
| Karyopharm Therapeutics INC. | $46.92 | 2025 | Xpovio |
| Agios Pharmaceuticals, INC. | $46.19 | 2023-2025 | Pyrukynd |
| Genmab U.S., INC. | $45.95 | 2023-2024 | Epkinly |
| Azurity Pharmaceuticals, INC. | $43.99 | 2024-2025 | Danziten, Vivimusta |
| Taiho Oncology, INC. | $41.67 | 2023 | |
| Legend Biotech USA INC. | $39.14 | 2025 | Carvykti |
| Verity Pharmaceuticals INC. | $37.31 | 2023-2024 | Trelstar |
| Telix Pharmaceuticals | $33.80 | 2024 | Illuccix |
| Amneal Pharmaceuticals LLC | $26.81 | 2023 | Avastin, Neupogen, Neulasta |
| Caris Mpi, INC. | $26.64 | 2025 | Mi Cancer Seek |
| Blue Earth Diagnostics | $26.45 | 2023 | |
| Fennec Pharmaceuticals, INC. | $25.00 | 2024 | Pedmark |
| Pharmacyclics LLC, An Abbvie Company | $24.61 | 2023 | Imbruvica |
| Kyowa Kirin, INC. | $22.28 | 2023 | Poteligeo |
| Springworks Therapeutics, INC. | $22.01 | 2025 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $21.11 | 2025 | Empaveli |
| G1 Therapeutics, INC. | $20.00 | 2023 | Cosela |
| Janssen Pharmaceuticals, INC | $12.44 | 2022 |
Drugs and devices associated with these payments
Enhertu $576Keytruda $536Reblozyl $472Ojjaara $435Verzenio $314Jaypirca $314Besremi $290Xt Cdx $279Opdivo $277Rybrevant $229Doptelet $220Elrexfio $216Padcev $213Carvykti $211Tukysa $192Monoferric $187Retevmo $181Zepzelca $177Ibrance $168Krazati $157Xtandi $153Alunbrig $150Adcetris $147Udenyca $142Bosulif $141Talzenna $128Jakafi $126Nubeqa $125Xofigo $125Lenvima $122Sarclisa $111Kisqali $110Ninlaro $106Onivyde $106Orgovyx $103Stivarga $103Monjuvi $102Venclexta $102Epkinly $99.05Enjaymo $93.99Libtayo $93.69Pluvicto $93.19Farxiga $91.89Imfinzi $91.22Welireg $90.55Mychoice Cdx $89.98Ultomiris $89.15Calquence $88.54Imbruvica $77.71Cablivi $74.02Polivy $71.59Inlyta $70.94Tibsovo $70.72Lynparza $68.53Illuccix $67.60Tecvayli $66.02Tecentriq $64.50Tevimbra $62.07Lorbrena $61.14Braftovi $61.14Mektovi $61.14Clonoseq $61.09Brukinsa $60.23Opdualag $59.73Myrisk $58.43Elahere $57.82Rezlidhia $56.68Tavalisse $56.68Qinlock $54.43Zynyz $54.15Yonsa $53.69Odomzo $53.69Provenge $52.39Octagam Immune Globulin (Human) $52.16Cabometyx $49.30Orserdu $48.59Optune Lua (Novottf-200t) $48.50Xpovio $46.92Tivdak $46.23Pyrukynd $46.19Besponsa $46.01Idhifa $45.88Talvey $45.19Precisetumor $43.15Inqovi $41.67Lonsurf $41.67Darzalex $41.57Xospata $40.74Vonjo $39.02Trelstar $37.31Phesgo $33.33Bavencio $32.50Itovebi $30.61Loqtorzi $28.68Tepmetko $27.68Erleada $27.67Zynlonta $27.61Scemblix $27.58Datroway $27.45Panzyga $26.84
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ochoa Planchart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.